Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: Comparison to long-standing diabetes and healthy individuals

被引:35
作者
Netea, MG
Hancu, N
Blok, WL
GrigorescuSido, P
Popa, L
Popa, V
vanderMeer, JWM
机构
[1] UNIV NIJMEGEN HOSP,DEPT INTERNAL MED,NL-6500 HB NIJMEGEN,NETHERLANDS
[2] DIABET CTR & CLIN,CLUJ NAPOCA 3400,ROMANIA
[3] PEDIAT CLIN 1,CLUJ NAPOCA 3400,ROMANIA
关键词
insulin-dependent diabetes mellitus; interleukin-1; tumour necrosis factor; interleukin-1 receptor antagonist;
D O I
10.1006/cyto.1996.0165
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin 1 beta (IL-1) and tumour necrosis factor alpha (TNF) are important for the beta cell lysis in insulin-dependent diabetes mellitus (IDDM), while IL-1 receptor antagonist (IL-1ra) is considered protective by blocking the effects of IL-1, Serum concentrations and es-vivo production of IL-1, TNF and IL-1ra were examined in 10 newly diagnosed IDDM (ND-IDDM) patients, and compared with 11 long-standing IDDM (LS-IDDM) patients and 14 healthy volunteers. Ex-vivo LPS-stimulated production of IL-1 in ND-IDDM patients was significantly increased compared with LS-IDDM patients and healthy controls, while TNF and IL-1ra synthesis did not differ significantly, IL-1ra/IL-1 ratio was significantly decreased in ND-IDDM, and returned to normal values in the LS-IDDM group. Circulating concentrations of IL-1ra in LS-IDDM patients were increased, These data suggest a proinflammatory imbalance in ND-IDDM patients and this may play an important role in beta cell loss. (C) 1997 Academic Press Limited.
引用
收藏
页码:284 / 287
页数:4
相关论文
共 22 条
[1]  
CASINIRAGGI V, 1995, J IMMUNOL, V154, P2434
[2]  
CHOMARAT P, 1995, J IMMUNOL, V154, P1432
[3]   IN-VITRO SECRETION OF INTERLEUKIN-1-BETA AND INTERFERON-GAMMA BY PERIPHERAL-BLOOD LYMPHOMONONUCLEAR CELLS IN DIABETIC-PATIENTS [J].
CIAMPOLILLO, A ;
GUASTAMACCHIA, E ;
CARAGIULO, L ;
LOLLINO, G ;
DEROBERTIS, O ;
LATTANZI, V ;
GIORGINO, R .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1993, 21 (2-3) :87-93
[4]  
DAYER-METROZ M-D, 1992, European Journal of Clinical Investigation, V22, pA50
[5]  
EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360
[6]   AN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN PROTECTS INSULIN-PRODUCING BETA-CELLS AGAINST SUPPRESSIVE EFFECTS OF INTERLEUKIN-1-BETA [J].
EIZIRIK, DL ;
TRACEY, DE ;
BENDTZEN, K ;
SANDLER, S .
DIABETOLOGIA, 1991, 34 (06) :445-448
[7]  
GIORDANO C, 1990, DIABETES NUTR METAB, V4, P277
[8]   TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide [J].
Kulseng, B ;
SkjakBraek, G ;
Folling, I ;
Espevik, T .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1996, 43 (03) :335-340
[9]   CYTOKINE PRODUCTION IN PATIENTS WITH NEWLY DIAGNOSED INSULIN-DEPENDENT (TYPE-I) DIABETES-MELLITUS [J].
LUGER, A ;
SCHERNTHANER, G ;
URBANSKI, A ;
LUGER, TA .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1988, 18 (03) :233-236
[10]   MONOKINE ANTAGONISM IS REDUCED IN PATIENTS WITH IDDM [J].
MANDRUPPOULSEN, T ;
POCIOT, F ;
MOLVIG, J ;
SHAPIRO, L ;
NILSSON, P ;
EMDAL, T ;
RODER, M ;
KJEMS, LL ;
DINARELLO, CA ;
NERUP, J .
DIABETES, 1994, 43 (10) :1242-1247